• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis welcomes Professor Stephen Smith as new Chairman
Share
News

ProAxsis welcomes Professor Stephen Smith as new Chairman

October 25, 2019
-
Posted by David Ribeiro

ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate effect.

Stephen has held senior leadership roles in the NHS and academia, including with the University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK’s first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge – Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive leadership experience, having served on the Boards of the National Healthcare Group in Singapore, the Royal Melbourne Hospital, and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “We’re delighted to welcome Professor Smith as the new Chairman of the Board of Directors, and believe that his vast experience in both healthcare and business will be a major asset to ProAxsis at this critical time for the company, as we seek to maximise the commercialisation of our product portfolio following the recent publication of new data for our neutrophil elastase point-of-care test.”

October 25, 2019

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19

December 10, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact …

Read More
December 10, 2020
Posted by David Ribeiro
News

ProAxsis expands COVID-19 research programme with new award

October 13, 2021
-
Posted by Jessica Robinson

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it has been awarded funding for a high …

Read More
October 13, 2021
Posted by Jessica Robinson
News

ProAxsis receives further backing from Invest Northern Ireland under EU investment

June 1, 2018
-
Posted by David Ribeiro

ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new …

Read More
June 1, 2018
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis supports next generation of scientists
NEXT POST →
New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • July 26, 2022
    ProAxsis announces additional key appointments
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis welcomes Professor Stephen Smith as new Chairman - ProAxsis